Concierge Cardiology · Chronic Management

Anticoagulation Therapy Management.

Personalized, physician-led anticoagulation therapy management with direct access to your cardiology team. Proactive monitoring. Faster interventions. Better outcomes.

Farhan Ayubi, MD, Vascular & Endovascular Surgeon

Approximately 6 million Americans take oral anticoagulants

Users U S

Warfarin is a top-3 drug cause of adverse events leading to ED visits (CDC)

Warfarin A D E

Each 10% improvement in TTR reduces stroke by 20% and major bleeding by 15%

Ttr Impact

Overview

Understanding anticoagulation therapy management.

Anticoagulation therapy is essential for millions of Americans — prescribed for atrial fibrillation, mechanical heart valves, venous thromboembolism, and hypercoagulable states. An estimated 6 million Americans take oral anticoagulants, split between warfarin (still used for mechanical valves and some valve disease) and direct oral anticoagulants (DOACs: apixaban, rivarelbaan, edoxaban, dabigatran). While anticoagulation dramatically reduces stroke and thromboembolism, it carries inherent bleeding risk that demands careful management. Warfarin remains one of the top causes of adverse drug events leading to emergency department visits in the United States. The narrow therapeutic window (typically INR 2.0-3.0 for AF, 2.5-3.5 for mechanical mitral valves) means that under-dosing exposes patients to clot risk while over-dosing causes bleeding. Even with DOACs, which require less monitoring, renal function changes, drug interactions, and procedural planning demand ongoing clinical oversight. Our concierge anticoagulation program provides precision warfarin management with home INR testing and same-day dose adjustments, DOAC optimization based on renal function and drug interactions, structured perioperative bridging protocols, and continuous bleeding risk assessment — achieving time in therapeutic range (TTR) rates that exceed 80%, far above the 55-65% typical of community practice.

Why Concierge

Why concierge cardiology for this condition.

Anticoagulation management is perhaps the clearest example of where concierge care provides measurable, life-saving value. Each percentage point improvement in time in therapeutic range (TTR) for warfarin patients translates to reduced stroke and bleeding events. Yet achieving high TTR requires frequent INR testing (weekly to biweekly), same-day dose adjustments, dietary counseling regarding vitamin K intake, and rapid communication when values are out of range. In standard anticoagulation clinics serving hundreds of patients, results may sit for 24-48 hours before dose changes are communicated. For DOAC patients, concierge care ensures annual renal function monitoring (more frequent for CKD patients, as creatinine clearance determines DOAC dosing), drug interaction surveillance with every new medication, and structured perioperative management with clear stop-and-restart protocols rather than ad hoc guessing. The result is optimal protection from both thrombosis and bleeding — the two sides of the anticoagulation balance.

What we monitor.

INR (warfarin patients): weekly during initiation, biweekly when stable, with home INR testing devices

Renal function (creatinine clearance): annually for DOAC patients, quarterly if CrCl < 60 mL/min

Complete blood count for anemia detection as an early sign of occult bleeding

Liver function for drug metabolism assessment and bleeding risk evaluation

Drug interaction review with every new medication, supplement, or OTC product

Bleeding risk reassessment using HAS-BLED score at every visit

Stool occult blood testing and hemoglobin trends for GI bleeding surveillance

Our management approach.

Home INR monitoring with patient self-testing and same-day physician-guided dose adjustments

DOAC selection based on renal function, weight, drug interactions, and patient preference (apixaban preferred in elderly/CKD)

Structured perioperative bridging protocols: standardized stop-and-restart timelines for surgeries and procedures

Vitamin K dietary counseling for warfarin patients: consistency rather than avoidance

Pharmacogenomic testing (CYP2C9, VKORC1) to guide initial warfarin dosing when appropriate

Left atrial appendage closure (Watchman device) evaluation for patients who cannot tolerate long-term anticoagulation

Emergency reversal planning: patient education on when to seek care, reversal agent awareness (idarucizumab, andexanet alfa)

Expected outcomes.

Time in therapeutic range (TTR) exceeding 80% for warfarin patients (vs. 55-65% nationally)

80-90% reduction in stroke risk for AF patients on optimized anticoagulation therapy

Major bleeding rate reduction through proactive HAS-BLED monitoring and drug interaction surveillance

Zero perioperative thromboembolic or bleeding events through standardized bridging protocols

Improved patient confidence and reduced anxiety about anticoagulation therapy through education and access

Related concierge services.

Hypertension Management

Heart Failure Monitoring

Atrial Fibrillation Management

Achieve safer, more effective anticoagulation with precision concierge management and home INR monitoring.

Direct physician access, proactive monitoring, and personalized care plans. Concierge cardiology starting at $295/month.

View Concierge Plans About Concierge Cardiology